Tag: biologic patents

Frederick Holland

Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market

Biosimilars can't enter the U.S. market until 12 years after a biologic's approval due to legal exclusivity, patent thickets, and high development costs-delaying affordable options for patients.